Sulagna Bhattacharya, Nanoscope Therapeutics CEO

March 30, 2023 11:43 AM EDT

Nanoscope’s eye disease gene therapy shows mixed results in PhII

Lei Lei Wu

News Reporter

Dallas-based biotech Nanoscope Therapeutics unveiled Phase II results on its gene therapy for a rare eye disease Thursday morning.

In the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

Sanofi touts $20B investment in US over five years